---
title: Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
date: '2024-06-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38828933/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240603181443&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: As compared with DVd therapy, BVd therapy conferred a significant
  benefit with respect to progression-free survival among patients who had relapsed
  or refractory multiple myeloma after at least one line of therapy. Most patients
  had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov
  number, NCT04246047; EudraCT number, ...'
disable_comments: true
---
CONCLUSIONS: As compared with DVd therapy, BVd therapy conferred a significant benefit with respect to progression-free survival among patients who had relapsed or refractory multiple myeloma after at least one line of therapy. Most patients had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov number, NCT04246047; EudraCT number, ...